Ischemic Stroke, Precerebral Occlusion DRG 062

DRG 062 covers ischemic stroke, precerebral occlusion, or transient ischemia cases where a thrombolytic agent was given and a Complication or Comorbidity is present; this classification reflects higher clinical complexity. Proper assignment of this Diagnosis-Related Group influences inpatient reimbursement by aligning payment with the additional resources associated with thrombolytic therapy and concurrent complications.

DRG 062 Overview

DRG 062 covers inpatient admissions for ischemic stroke, precerebral occlusion, or transient ischemia where a thrombolytic agent was administered and there is a Complication or Comorbidity. This Diagnosis-Related Group groups patients by the clinical event and the use of thrombolytic therapy, with added resource considerations when a Complication or Comorbidity is present. It matters for Medicare reimbursement because payment is adjusted based on the clinical complexity and therapies provided during the hospital stay. Accurate coding of the thrombolytic administration and the presence of Complications or Comorbidities affects the Diagnosis-Related Group assignment and payment.

Acute reperfusion strategy trials focusing on early administration and delivery methods of thrombolytic therapy in patients presenting with ischemic stroke or transient ischemic attack within the therapeutic time window. These studies enroll patients with confirmed precerebral or intracranial large-vessel occlusions who are eligible for systemic thrombolytics, and often compare time-to-treatment protocols, adjunctive imaging selection criteria, or novel administration techniques to optimize clot dissolution. Results inform in-hospital stroke pathways and resource allocation decisions for emergency departments and stroke units, impacting length of stay, complication rates, and short-term reimbursement drivers for this DRG.
Comparative effectiveness research evaluating adjunctive acute care interventions and complication prevention in thrombolysed stroke patients with complications or comorbid conditions (the CC population). Trials in this area test different blood pressure management strategies, glycemic control protocols, or prophylactic measures against hemorrhagic transformation and medical complications in patients with significant comorbid cardiovascular or metabolic disease. Findings are highly relevant to clinicians and payers because they can reduce complication-related utilization, readmissions, and cost variability within this DRG by identifying care bundles that improve safety without prolonging inpatient stays.
Post-discharge outcomes and care-transition studies examining early rehabilitation intensity, secondary prevention adherence, and coordinated outpatient follow-up for patients discharged after ischemic stroke who received thrombolytic therapy. These longitudinal studies follow heterogeneous survivors—many older with functional deficits and comorbidities—to assess interventions that reduce functional decline, recurrent vascular events, and rehospitalization over 30–365 days. For providers and payers, evidence from these studies guides discharge planning, outpatient service coverage, and investment in transitional care programs that can lower downstream costs and improve quality metrics associated with this DRG.

Acute reperfusion strategy trials focusing on early administration and delivery methods of thrombolytic therapy in patients presenting with ischemic stroke or transient ischemic attack within the therapeutic time window. These studies enroll patients with confirmed precerebral or intracranial large-vessel occlusions who are eligible for systemic thrombolytics, and often compare time-to-treatment protocols, adjunctive imaging selection criteria, or novel administration techniques to optimize clot dissolution. Results inform in-hospital stroke pathways and resource allocation decisions for emergency departments and stroke units, impacting length of stay, complication rates, and short-term reimbursement drivers for this DRG.
Comparative effectiveness research evaluating adjunctive acute care interventions and complication prevention in thrombolysed stroke patients with complications or comorbid conditions (the CC population). Trials in this area test different blood pressure management strategies, glycemic control protocols, or prophylactic measures against hemorrhagic transformation and medical complications in patients with significant comorbid cardiovascular or metabolic disease. Findings are highly relevant to clinicians and payers because they can reduce complication-related utilization, readmissions, and cost variability within this DRG by identifying care bundles that improve safety without prolonging inpatient stays.
Post-discharge outcomes and care-transition studies examining early rehabilitation intensity, secondary prevention adherence, and coordinated outpatient follow-up for patients discharged after ischemic stroke who received thrombolytic therapy. These longitudinal studies follow heterogeneous survivors—many older with functional deficits and comorbidities—to assess interventions that reduce functional decline, recurrent vascular events, and rehospitalization over 30–365 days. For providers and payers, evidence from these studies guides discharge planning, outpatient service coverage, and investment in transitional care programs that can lower downstream costs and improve quality metrics associated with this DRG.

OpenPayer

Summary & Overview

Ischemic Stroke with Thrombolytic Agent and CC: Inpatient Reimbursement Overview

DRG 062 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes